Clinical and urodynamic efficacy of oxybutynin and verapamil in the treatment of nocturnal enuresis after formation of orthotopic ileal neobladders. A prospective, randomized, crossover study.
OBJECTIVE
To evaluate the efficacy of two drugs: the anticholinergic agent oxybutynin (Ditropan) and the calcium channel blocker verapamil (Isoptin) in the management of nocturnal enuresis in patients with orthotopic ileal reservoirs.


METHODS
The study population comprised 20 male enuretic patients who had undergone radical cystoprostatectomy and formation of an orthotopic ileal reservoir (hemi-Kock or W-neobladder). All patients were clinically evaluated regarding their continence state. Basal medium-fill enterocystometry was performed for every patient. The patients were randomized on entry into one of the two arms of the study: oxybutynin followed by verapamil (n =10); or verapamil followed by oxybutynin (n = 10). Each group received both drugs for a period of 2 weeks each. After administration of each drug, patients were re-evaluated both clinically and urodynamically.


RESULTS
Oxybutynin and verapamil improved continence status in 70% and 55% of the patients, respectively. Both drugs significantly increased the bladder volume at first desire, at normal desire and at the maximum enterocystometric capacity. The maximum enterocystometric capacity increased from 585+/-148.6 ml at baseline to 667.5+/-180.8 and 621.05+/-170.5 ml after administration of oxybutynin and verapamil, respectively. Despite this, there was no significant change in any of the pressure parameters with the exception of the basal pressure at maximum enterocystometric capacity, which decreased significantly from 20.1+/-8.3 cmH2O at baseline to 16.07+/-5.1 cmH2O after administration of verapamil. The number of uninhibited contractions in the last 5 min of filling decreased significantly from 3.6+/-0.7 at baseline to 1.9+/-1.2 after administration of oxybutynin and to 2.1+/-1.26 after administration of verapamil. The amplitude of maximum uninhibited contraction decreased from 41.15+/-9.1 cmH2O at baseline to 34.95+/-12.77 and 33.25+/-11.52 cmH2O after treatment with oxybutynin and verapamil, respectively. Neither drug significantly changed the initial, late or total compliance of the pouch. No significant side-effects occurred with either drug.


CONCLUSIONS
Both drugs used in this study had beneficial effects on the continence status of our patients, with minimal side-effects. Both drugs clinically improved nocturnal incontinence after radical cystoprostatectomy and formation of orthotopic ileal reservoirs, which was verified by the associated improvements in urodynamic characteristics.
El-Bahnasawy
Magdy S
MS
Urology & Nephrology Center, Mansoura University, Mansoura, Egypt. mbahnasawy@yahoo.com
Shaaban
Hani
H
Gomha
Mohamed A
MA
Nabeeh
Adel
A
D000328:Adult; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D039021:Colonic Pouches; D018592:Cross-Over Studies; D015653:Cystectomy; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D053206:Nocturnal Enuresis / Q000188:drug therapy*; D011446:Prospective Studies; D011468:Prostatectomy; D016896:Treatment Outcome; D014700:Verapamil / Q000494:pharmacology / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D018680:Cholinergic Antagonists; D008333:Mandelic Acids; D014700:Verapamil; C005419:oxybutynin